Subacute combined degeneration (SCD) is a neurological disease characterized by damage to the spinal cord and peripheral nervous system. The main pathogenetic mechanism for the development of SCD is vitamin B12 deficiency and its effect on myelination of nerve fibers. As a result of this disease, both sensory and motor disorders are observed. It is important to note that this condition can develop not only due to a deficiency of this vitamin, but also in the context of the interaction of various factors, including exposure to toxic substances and certain concomitant diseases. The clinical picture includes neurological symptoms, coordination disorders, as well as manifestations from the musculoskeletal system, which makes the diagnosis of SCD extremely important for adequate treatment and prevention.
History of the disease and interesting historical facts
The history of subacute combined degeneration is closely linked to the discovery of vitamin B12. In 1926, this vitamin was found to be a key factor in the treatment of pernicious anemia, which often accompanies SKD. However, the link between vitamin B12 deficiency and the development of neurological disorders only became clear in 1948, when a group of researchers identified the important role of this vitamin in maintaining the health of the nervous system. In the 1950s, numerous clinical studies were conducted confirming the effectiveness of vitamin therapy in the treatment of SKD. This discovery became the basis for the development of new therapeutic strategies and approaches to the treatment of diseases associated with vitamin deficiency.
Epidemiology
The recognition of the epidemiology of subacute combined degeneration is supported by factors associated with vitamin B12 deficiency. According to the World Health Organization, vitamin B12 deficiency occurs in 10-15% of the population in developing countries and about 5% in developed countries. The elderly are shown to be particularly at risk, since vitamin absorption declines with age. In addition, there is a high prevalence of PCD among individuals with gastrointestinal diseases such as Hartnup disease, celiac disease, and atrophic gastritis. Epidemiological studies also indicate a higher incidence in farmers and workers exposed to heavy metals and toxic substances.
Genetic predisposition to this disease
Genetic predisposition to subacute combined degeneration is mainly associated with mutations in genes responsible for the metabolism of vitamin B12 and the synthesis of enzymes involved in the use of this vitamin. One of the key genes involved in this process is the MTHFR (methylenetetrahydrofolate reductase) gene, mutations in which can impair the absorption of folate and vitamin B12. Other important gene variants associated with vitamin B12 deficiency include TC (transport protein), which is responsible for transporting the vitamin into cells, as well as some genes regulating the activity of mesodermal growth factor. There are also associations between vitamin B12 deficiency and polymorphisms in genes responsible for homocysteine metabolism.
Risk factors for the development of this disease
There are several signs and factors that may predispose to the development of subacute combined degeneration. The main risk factors include:
- Vitamin B12 deficiency resulting from poor nutrition or absorption.
- Gastrointestinal diseases such as atrophic gastritis, celiac disease and diseases causing malabsorption.
- Alcoholism, which also leads to impaired absorption of vitamins.
- Older age, as nutrient absorption may decrease with age.
- Chronic diseases such as diabetes, which can complicate metabolism, including vitamin metabolism.
- Damage such as ionizing radiation and some toxic substances in the workplace.
Diagnosis of this disease
Diagnosis of subacute combined degeneration involves a comprehensive approach, including a number of methods and tests. The main symptoms are:
- Muscle weakness and atrophy.
- Impaired coordination and balance.
- Paresthesia and numbness in the extremities.
- Hearing and vision impairments.
Laboratory tests:
- Determination of the level of vitamin B12 in the blood.
- Tests for homocysteine and methylmalonic acid markers.
Radiological examinations include:
- Magnetic resonance imaging (MRI) to assess the condition of the spinal cord and myelin.
Diagnostic methods also include methods for assessing nervous system function and differential diagnosis to exclude other neurological diseases.
Treatment
Treatment of subacute combined degeneration is aimed at eliminating vitamin B12 deficiency and restoring nervous system functions. The main approaches to treatment are:
- General treatment: administration of vitamin-forming drugs and nutritional correction to replenish the deficiency of vitamin B12.
- Pharmacological treatment: use of anti-pain medications such as hydroxycobalamin in the early stages of the disease.
- Surgical treatment: In rare cases where there is significant narrowing of the spinal canal, surgery may be required.
- Other treatments include physical therapy, occupational therapy and general rehabilitation to restore motor function and improve quality of life.
List of medications used to treat this disease
The following drugs are used to treat subacute combined degeneration:
- Hydroxycobalamin (vitamin B12).
- Methionine (metabolism supplement).
- Folic acid.
- Calcium and drugs that improve microcirculation.
Disease monitoring
Monitoring of patients with subacute combined degeneration includes regular control tests for vitamin B12 and homocysteine levels, as well as functional tests to assess the state of the nervous system. The prognosis depends on the timeliness of treatment: with early diagnosis and treatment, symptoms can be significantly reduced. However, complications are possible, including persistent neurological disorders and limitations in functionality.
Age-related features of the disease
Subacute combined degeneration may behave differently depending on the patient's age. In older people, the disease is more often found against the background of other concomitant diseases and with concomitant nutritional deficiency. In younger people, as a rule, the disease responds more effectively to therapy, especially with adequate treatment of vitamin B12 deficiency. It is also important to consider genetic predisposition and concomitant risk factors, the combination of which can aggravate or alleviate the course of the disease in different age groups.
Questions and Answers
- What is subacute combined degeneration? Subacute combined degeneration is a neurological disorder associated with vitamin B12 deficiency that results in damage to the spinal cord and nervous system.
- What are the main symptoms of PCD? The main symptoms include muscle weakness and atrophy, loss of coordination, paresthesia, and problems with hearing and vision.
- What factors increase the risk of developing PCD? Major risk factors include vitamin B12 deficiency, gastrointestinal disease and older age.
- What is needed to diagnose PCD? Diagnosis of PCD includes analysis of vitamin B12 levels, MRI, and assessment of neurological status.
- How is PCD treated? Treatment includes vitamin B12 supplementation, nutritional adjustments and rehabilitation in case of severe symptoms.
